Major Events - Universal Medical (02666) plans to invest 15.03 million yuan to establish a joint venture that will create a collaborative platform integrating policy alignment, technology transfer, and clinical validation [1] - Fosun Pharma (02196) subsidiary has had its drug registration application for polyethylene glycol electrolyte solution accepted by the National Medical Products Administration [1] - China Biologic Products (01177) received approval from NMPA for the clinical trial application of LM-350 "CDH17 ADC" [1] - Xianruida Medical-B (06669) has received approval from the National Medical Products Administration for the registration of its coronary overall exchange balloon dilation catheter [1] - Meili Tianyuan Medical Health (02373) subsidiary plans to acquire medical and beauty assets related to Nairuier for 40 million yuan, adding 19 direct-operated stores [1] - China Tongru (01763) has exported its self-produced irradiation equipment to the Latin American market for the first time [1] Operating Performance - Trip.com Group-S (09961) reported a third-quarter net profit of 19.89 billion yuan, an increase of 194.01% year-on-year [1] - H&H International Holdings (01112) reported a 12.0% year-on-year increase in total revenue for the first three quarters [1] - Weibo-SW (09898) reported a net profit attributable to shareholders of 454 million USD for the third quarter, an increase of 55.43% year-on-year [1] - Baidu Group-SW (09888) reported total revenue of 31.2 billion yuan in the third quarter, with AI new business revenue growing over 50% year-on-year [1] - Xiaomi Group-W (01810) achieved a record adjusted net profit of 11.31 billion yuan in the third quarter, with smartphone shipments increasing year-on-year for nine consecutive quarters [1] - China Oriental Group (00581) reported sales of approximately 2.1 million tons of self-produced steel products in the third quarter [1] - BOSS Zhipin-W (02076) reported an adjusted net profit of approximately 999.2 million yuan in the third quarter, an increase of 34.2% year-on-year [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating progress in the company's product pipeline for treating chronic constipation [1] Group 1 - The drug is classified as a chemical medication intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder, including this drug, is approximately RMB 6.21 million as of October 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 873 million in 2024 [1] Group 3: Regulatory Status - The drug must obtain drug registration approval and fulfill other requirements before commercial production can commence [1] - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China, indicating progress in the commercialization of this product for chronic constipation treatment [1][1]. Group 1: Company Developments - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1]. - As of October 2025, the total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder products, including this drug, is approximately RMB 6.21 million (unaudited) [1]. - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]. Group 2: Market Potential - According to the latest data from IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 873 million in 2024 [1].

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powders, including this drug, is approximately RMB 6.21 million as of October 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 873 million in 2024 [1] Group 3: Regulatory Status - The drug must obtain drug registration approval and fulfill other requirements before commercial production can commence [1] - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration [1] Group 1: Drug Development - The Compound Polyethylene Glycol (3350) Electrolyte Powder is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - As of October 2025, the group has invested approximately RMB 6.21 million (unaudited) in the research and development of the Compound Polyethylene Glycol Electrolyte Powder series, including this drug [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the chronic constipation treatment market [1] Company Summary - Fosun Pharma's Polyethylene Glycol (3350) Electrolyte Powder is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The expected sales revenue for Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 873 million in 2024, according to the latest data from IQVIA CHPA [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Polyethylene Glycol (3350) Electrolyte Solution by the National Medical Products Administration, aimed at treating chronic constipation [1] Company Summary - Fosun Pharma's Polyethylene Glycol (3350) Electrolyte Solution is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The expected sales revenue for Polyethylene Glycol Electrolyte Solution in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 873 million in 2024 according to IQVIA CHPA data [1]

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a new medication aimed at treating chronic constipation in children aged 1 to 11 years old, as well as fecal impaction in children aged 5 to 11 years old [1] Group 1 - The drug, a compound polyethylene glycol (3350) electrolyte solution, is specifically designed for pediatric use [1] - The approval indicates a potential expansion in the company's product offerings within the pediatric healthcare market [1]